Decoy Therapeutics is trading 5.7% down at $1.75, with no clearly identified catalyst for the October 2 decline. - The latest preclinical update was reported September 29, and the investor presentation was scheduled for October 1; neither is a new October 2 event. - Major U.S. indices are higher, so the market context does not explain the decline as a broad-market selloff. - An October 2 report notes a sharp reduction in the consensus price target but does not establish it as the cause.